-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $6

Benzinga·04/01/2025 12:07:25
Listen to the news
Jefferies analyst Roger Song initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $6.